Celldex Therapeutics

Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.

Celldex Therapeutics reports significant progress in Phase 3 trials of barzolvolimab for chronic spontaneous urticaria (CSU), with active enrollment ongoing across 40 countries and 500 sites.

• The global chronic spontaneous urticaria (CSU) market is projected to grow from $15.1 million in 2024 to $36 billion by 2035, driven by rising diagnosis rates and innovative biologic therapies. • Pharmaceutical giants including Novartis, Sanofi, Roche, and AstraZeneca are advancing promising treatments beyond traditional antihistamines, with BTK inhibitors like remibrutinib and rilzabrutinib showing significant potential in clinical trials. • Treatment paradigms are shifting from conventional approaches toward personalized medicine and targeted therapies, offering new hope for the approximately 2.8 million CSU patients across major markets who often experience inadequate symptom control.

The ACTG has initiated the ACACIA (A5417) study, a Phase 2 trial, to assess the safety and efficacy of broadly neutralizing antibodies (bNAbs) in HIV treatment.

Celldex Therapeutics has begun a Phase 2 clinical trial to evaluate barzolvolimab for treating moderate to severe atopic dermatitis, a chronic inflammatory skin condition.

The urticaria treatment landscape is evolving, with over 20 companies developing more than 25 novel therapies to address unmet patient needs.

• Evommune has raised $115 million in Series C funding to support Phase 2 trials for EVO756 and EVO301, targeting chronic immune conditions like urticaria and atopic dermatitis. • EVO756, an oral small molecule, is being developed as a potential first-in-class treatment for mast cell-driven conditions by blocking the MRGPRX2 receptor. • EVO301, a fusion protein targeting IL-18, is under evaluation for atopic dermatitis, showcasing a compelling clinical profile with convenient dosing intervals in Phase 1 testing. • The funding will support multiple data readouts with potential for an IPO, as the company advances its pipeline for inflammatory diseases.

Barzolvolimab significantly improved outcomes in patients with cold urticaria and symptomatic dermographism compared to placebo, as shown in a phase II trial.

Celldex Therapeutics' barzolvolimab demonstrates clinical benefit in chronic inducible urticaria (CIndU) patients in a randomized, placebo-controlled study.

Celldex's barzolvolimab demonstrated significant clinical benefit in patients with chronic inducible urticaria (CIndU) in a randomized, placebo-controlled Phase 2 study.